Fabry Disease Market Growth to Surge During Forecast Period (2024-2034), Says DelveInsight

Strategic Insights -

The Fabry disease market size was valued at approximately $1,700 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034). The introduction of upcoming therapies like ST-920 is expected to drive changes in the overall Fabry disease market size in the coming years. The growing Fabry disease pool is expected to propel the treatment market, adding opportunities for new pharma players.

Key Takeaways:

  • The Fabry disease market size was valued at approximately $1,700 million in 2024.
  • The market is anticipated to grow with a significant CAGR during the study period (2020-2034).
  • The introduction of upcoming therapies like ST-920 is expected to drive changes in the overall Fabry disease market size in the coming years.
  • The growing Fabry disease pool is expected to propel the treatment market, adding opportunities for new pharma players.
  • The Fabry disease market is driven by the increasing prevalence and awareness of the disease.
  • The market is expected to grow due to the launching of various multiple-stage Fabry disease pipeline products.
  • The Fabry disease therapies like ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others are expected to contribute to the growth of the market.
  • The Fabry disease market is expected to witness significant growth in the 7 major markets (7MM) expected to reach USD 14,549.4 Million by 2030.

Statistics:

  • The Fabry disease market size was valued at approximately $1,700 million in 2024.
  • The market is anticipated to grow with a significant CAGR during the study period (2020-2034).
  • The Fabry disease market is expected to grow due to the launching of various multiple-stage Fabry disease pipeline products.
  • The Fabry disease therapies like ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others are expected to contribute to the growth of the market.
  • The Fabry disease market is expected to witness significant growth in the 7 major markets (7MM) expected to reach USD 14,549.4 Million by 2030.

Sources:

  • DelveInsight's "Fabry Disease Market Insights, Epidemiology, and Market Forecast-2034" report.
  • M2 PressWIRE-August 14, 2025-.